FTSE 100 gains slightly as BT, AstraZeneca hand hold London equities


  • FTSE 100 traded marginally higher, led by shares of BT and AstraZeneca
  • BT jumped nearly 6 per cent after Patrick Drahi bought 12 per cent stake
  • AstraZeneca, up 2 per cent, supported the index further 

UK shares traded flat in the early afternoon with the benchmark FTSE 100 oscillating marginally higher as shares of the heavyweight BT Plc (LON: BT.A) and AstraZeneca Plc (LON: AZN) provided the major positive points to the index. The global equity sentiments have been battered by the worries of mounting inflation, the jittery escalated after the Chinese factory gate prices registered a 9 per cent growth, the highest since September 2008.

The lost confidence was evident from the choppy Wall Street with the leading indicator Dow Industrials sliding more than 0.40 per cent at the close, the losses of S&P 500 were contained under 0.20 per cent, whereas the tech benchmark Nasdaq Composite finished moderately lower after diving in the late trades.

According to the London Stock Exchange, the headline FTSE 100 was trading at 7,100.76, up 0.28 per cent, from the previous close of 7,081.01. The index has been duly supported by the sharp spike in some of the blue-chip stocks with BT and AstraZeneca hand holding the uptick.

The stock of BT jumped nearly 6 per cent after the Switzerland-based telecom billionaire Patrick Drahi bought a 12.1 per cent stake of BT’s issued share capital, effectively becoming the single largest shareholder in the company. Altice UK, a wholly-owned company by Drahi, acted as the investor to buy as much as 1.2 billion shares of BT.

Shares of BT, the London-headquartered multinational telecom giant, hit a fresh 52-week high following the major development. As per the trading data available with the LSE, the stock soared as much as 5.85 per cent to a new 52-week high of GBX 193.88 from the last close of GBX 183.15. The stock of BT was the second-biggest gainer among the 101 constituents of FTSE 100.

BT Group shares (10 June)

Image Source: REFINITIV

Meanwhile, the shares of AstraZeneca rose approximately 2 per cent, emerging as the biggest contributors to the key index. The stock jumped 1.92 per cent to at least a six month high of GBX 8,286 from the previous close of GBX 8,130 apiece.

Also Read | Which UK Companies Pay The Best Dividend?

On the contrary, the mid-cap indicator FTSE 250 dropped more than 0.50 per cent, largely due to persisting weakness in the mid-cap constituents, while the broader stock indices including the FTSE 350 and FTSE All-Share traded 0.14 and 0.13 per cent higher, respectively.

The domestic market participants have been awaiting the macroeconomic releases with the Office for National Statistics (ONS) lined up to declare the balance of trade, construction output, industrial and manufacturing production for the month of April.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is not authorised or regulated by the Financial Conduct Authority to provide regulated advice. The purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. The Content is guidance about the different types of investments that are available and sets out general principles to continue before making investment decisions. Kalkine Media is neither authorised nor qualified to provide regulated investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from an appropriately authorised and/or qualified financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.